summary
Introduced
02/03/2026
02/03/2026
In Committee
02/17/2026
02/17/2026
Crossed Over
Passed
Dead
Introduced Session
104th General Assembly
Bill Summary
Amends the Illinois Controlled Substances Act. Provides that the Prescription Monitoring Program does not apply to testosterone, mifepristone, misoprostol, GnRH analogues, or estrogen. Provides that the Department of Human Services shall purge from the records of the Prescription Monitoring Program all existing information concerning the prescribing or dispensing of testosterone, including any such information contained in the central repository or database, on or before January 1, 2027, and shall ensure that no further records concerning the prescribing and dispensing of testosterone are created or maintained by the Prescription Monitoring Program. Provides that the Department shall update and adopt rules consistent with the provision no later than January 1, 2027. Effective immediately.
AI Summary
This bill amends the Illinois Controlled Substances Act to exempt certain medications from the state's Prescription Monitoring Program, which is a system designed to track the prescribing and dispensing of controlled substances. Specifically, testosterone, mifepristone, misoprostol, GnRH analogues (hormone-regulating drugs), and estrogen will no longer be subject to this tracking. Furthermore, the Department of Human Services is mandated to completely remove all existing records related to the prescribing and dispensing of testosterone from the Prescription Monitoring Program by January 1, 2027, and is prohibited from creating or keeping any new records of testosterone prescriptions thereafter, with the Department required to update its rules to reflect these changes by the same date.
Committee Categories
Government Affairs
Sponsors (2)
Last Action
Assigned to Executive (on 02/17/2026)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...